Vorinostat is victorious in GVHD prevention

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations


In this issue of Blood, Choi et al describe the clinical efficacy of histone deacetylase inhibitor (HDACi) vorinostat in the prevention of severe acute graft-versus-host disease (aGVHD) in a high-risk setting: myeloablative, unrelated-donor allogeneic hematopoietic cell transplantation (HCT).1

Original languageEnglish (US)
Pages (from-to)1690-1691
Number of pages2
Issue number15
StatePublished - Oct 12 2017

Fingerprint Dive into the research topics of 'Vorinostat is victorious in GVHD prevention'. Together they form a unique fingerprint.

Cite this